Abstract 29
Introduction 46
Salivaricin P is a two-component class IIb bacteriocin produced by the porcine 47 7 by Morgan et al., 2005 (21) . The L. innocua cultures (in triplicate) were diluted 1 in 146 10 and 150 l of each culture was added to 500 l microfuge tubes which contained 147 Sln1 or Sln2 individually (at concentrations of 0 nM, 40 nM, 80 nM, 120 nM, 160 nM 148 and 200 nM). Tubes were left at room temperature for approximately 20 min (to 149 enable binding of peptide molecules to cell surfaces) prior to centrifuging at 13,000  150 g for 30 seconds. Supernatants were removed from each tube and cell pellets were 151 washed twice with GM17 broth (supplemented with 0.1% (vol/vol) Tween 80). Cell 152 pellets were resuspended in 150 l of fresh broth. Cells that had been exposed to Sln1 153 alone were added to microtiter wells which contained Sln2, and cells that had been 154 exposed to Sln2 alone were added to microtiter wells which contained Sln1 (at 155 combining with the wild-type peptide using the microtiter based assay system 165 described above. The variants displaying lowest MIC 50 when combined with the wild-166 type complementary peptide were then similarly combined with one another to 167 determine their specific antilisterial activity. 168
Sln1 and Sln2 are active at nanomolar concentrations in an optimal ratio 171 of 1:1. The salivaricin P peptides, Sln1 and Sln2, were generated by peptide synthesis. 172 MS analysis confirmed that the masses of the synthetic peptides were identical to 173 those produced by Lb. salviarius DPC6005 and antimicrobial activity assays using 174
Listeria as the indicator established that the natural and synthetic peptides have equal 175
potency. The combined concentrations of Sln1 and Sln2 that were required to inhibit 176 the growth of the indicator strain, L. innocua DPC3572, by 50% were plotted as an 177 isobologram (Fig. 1) . As is the case for another class IIb bacteriocin, lactococcin G 178 (22), the addition of Tween 80 to the culture medium (final concentration, 0.1% 179 [vol/vol] ) increased the assay sensitivity almost 10-fold (data not shown), and thus 180 was incorporated in all cases. When assessed individually both Sln1 and Sln2 181 displayed activity at micromolar concentrations against L. innocua DPC3572. 182
However, Sln1 (MIC 50 of 5M) has ten-fold higher individual activity than Sln2 183 (MIC 50 of 50 M). Studies with combinations of these peptides revealed that activity 184 was optimal when Sln1 and Sln2 were combined at equal concentrations. This optimal 185 ratio is consistent with that reported when the synthetic components of salivaricin 186 CRL1328, with which salivaricin P shares 95% identity (Fig. 2) , were tested using an 187
Enterococcus faecalis indicator strain (32). Here we also establish that when Sln1 and 188
Sln2 are combined the corresponding MIC 50 value is 50 nM (Fig. 1) , one hundred-fold 189 more active than Sln1 alone. 190
191
Salivaricin P peptides act sequentially to kill target cells at nanomolar 192 concentrations. The Sln1 and Sln2 peptides were subjected to further investigation in 193 order to determine whether or not they function in a sequential manner. It was 194 apparent that growth inhibition was not observed when L. innocua DPC3572 was firstexposed to Sln1, followed by extensive washing and subsequent addition of Sln2. 196 However, when the indicator was pre-treated with Sln2, prior to extensive washing 197 and subsequent addition of Sln1, the degree of inhibition was comparable to that 198 achieved when both peptides were added simultaneously (Fig. 3 ). This confirms a 199 sequential mode of action and suggests that Sln2 is likely to be the receptor binding 200 component of the bacteriocin. 201
202
Design of salivaricin P variant peptides. Trypsin is predicted to specifically 203 cleave at two locations in Sln1, i.e. after both Lys1 and Arg2, which would result in a 204 43 amino acid (aa) product with a molecular mass of 3812 Da. It is also predicted to 205 cleave at two locations in Sln2, after Lys1 and Arg10, which would result in a 9 aa 206 fragment of 880 Da and 36 aa fragment of 3293 Da. These predictions were 207 confirmed by MALDI-TOF MS analysis of the peptides before and after tryptic 208 digestion (Table 2) , and the effect of trypsin digestion on the activity of salivaricin P 209 is presented in Figure 4 . The residues that are lost as a consequence of trypsin 210 digestion are, due to their cationic nature, likely important for bacteriocin activity. In 211 both class I and class IIa bacteriocins these residues have frequently been found to 212 play an important role in mediating the initial interaction with the anionic target cells 213 via electrostatic interactions (3, 4, 17) . Indeed, recent studies with the most 214 extensively studied class IIb bacteriocin, lactococcin G, also revealed an important 215 role for such residues in positioning the cationic C-termini of the bacteriocin 216 components inside the target cell (23, 25, 27 ). Here we sought to maintain the potent 217 antilisterial activity of the salivaricin P components while establishing a trypsin 218 resistant phenotype. Therefore, to preserve the function of the positively charged 219 trypsin-specific residues of salivaricin P, a variety of conservative changes to Sln1 220 and Sln2 were investigated (Table 1) . These alterations included the removal and/or 221 replacement by histidine of the trypsin-sensitive Lys and Arg residues as well as the 222 insertion of proline residues adjacent to trypsin-specific sites to hinder the protease 223 activity. Initially, the creation of Sln1-1, which lacks an N-terminal Lys, was 224 synthesized in order to reveal the impact of partial trypsin digestion on the specific 225 anti-Listeria activity of Sln1. A number of other peptides were also designed with a 226 view to enhancing trypsin resistance. These included Sln1-2, a variant of Sln1 227 containing a His rather than Lys1-Arg2 at the N-terminus, as well as Sln1-3 and Sln1-228 4, both of which contain His residues in place of either Lys1 or Arg2 in addition to the 229 insertion of a proline residue adjacent to the other trypsin-sensitive residue. Sln1-5 230 was also designed to include an additional Pro residue after the N-terminal Lys, 231 together with the removal of a glycine such that both trypsin-sensitive residues are 232 bordered at the carboxyl side by a proline. With respect to Sln2, a variant which 233 contained an Arg10His substitution, Sln2-1, was predicted to confer trypsin resistance 234 at this location in Sln2. However, this variant retains a trypsin cleavage site at Lys1, 235 digestion of which is predicted to result in a 45 aa product of 4137 Da. Sln2-2 and 236 Sln2-3 were designed to address this by combining the Arg10His substitution with a 237
Pro insertion at the carboxyl side of Lys1 or a Lys1His substitution, respectively. Two 238 truncated derivatives of Sln2 were also synthesized, Sln2-4, consisting of the 10 N-239 terminal aa fragment cleaved upon tryptic digestion of Sln2, and Sln2-5, which lacks 240 the nine N-terminal amino acids of Sln2 but contains a Pro insertion following the 241 now N-terminally located Arg residue. 242 innocua DPC3572 by combining each variant in equimolar concentrations with the 246 wild-type version of the complementary peptide (Table 1) . MS analysis was 247 performed to assess the trypsin sensitivity of each of the synthetic variants (Table 2) . 248
This revealed that the purified Sln1 peptide and variants thereof are very sensitive to 249 oxidation (as demonstrated by an associated 16 Da increase in the molecular mass of 250 the peptide) which negatively impacted on antimicrobial activity. Studies with Sln1-1 251 revealed that the N-terminal Lys of the peptide is not essential as the MIC 50 of Sln1-1, 252 when combined with Sln2, was 80 nM. However, as expected, this peptide remains 253 susceptible to tryptic digestion, which results in a 3812 Da cleavage product (Table  254 2). When this change was coupled with an Arg2His alteration to generate the trypsin 255 resistant variant Sln1-2 (Table 2), the corresponding peptide was now four-fold less 256 active (MIC 50 of 200 nM) than Sln1 (MIC 50 of 50 nM), when combined with Sln2. 257
Crucially, however, this peptide had a trypsin resistant phenotype. These MIC 50 values 258 were further improved to 100 nM and 130 nM in the trypsin resistant peptides Sln1-3 259 and Sln1-4, respectively (Table 2) . However, of all the trypsin-resistant Sln1 variants, 260
Sln1-5 was most impressive in that its potency against L. innocua DPC3572 is 261 comparable to that of wild type Sln1, exhibiting a MIC 50 of 80 nM (when combined 262 with Sln2). 263
Finally, as noted above, the Sln1 peptide and its variants are susceptible to 264 oxidation. This phenomenon has previously been associated with a number of other 265 class II bacteriocins (13, 16, 20) and has been attributed to the oxidation of the 266 sulphur atom of methionine residues resulting in the formation of methionine 267 sulfoxide. To determine if the oxidation of Sln1 is due to the methionine residue at 268 position 37 an additional Sln1 variant, Sln1-6, which contains a Met37Leuthan two-fold (MIC 50 of 120 nM), compared to that of the wild type, thereby 271 indicating the importance of this methionine residue for activity, this variant did not 272 display susceptibility to oxidation, confirming that the Met37 residue is the oxidation-273 sensitive residue. 274 275 Activity and protease resistance of Sln2 variants. Trypsin also cleaves at 276 two sites within Sln2 resulting in the removal of Lys1 as well as a further nine aa N-277 terminal fragment upon cleavage at Arg10 ( Table 2) . Substitution of Sln2Arg10 with 278
His (Sln2-1) resulted in a four-fold decrease in activity when combined with wild type 279 Sln1 (Table 1 ). An associated cleavage product of 4137 Da upon tryptic digestion 280 (Table 2) confirmed trypsin resistance at this position. When this modification was 281 coupled with the insertion of a Pro residue following Lys1 (Sln2-2), complete trypsin 282 resistance was achieved without further reducing antimicrobial activity (Tables 1 and  283 2). However, substituting Lys1 as well as Arg10 with His (Sln2-3) also resulted in 284 trypsin resistance (Table 2 ) and led to an improvement in specific activity (MIC 50 of 285 120 nM), when combined with wild-type Sln1. The 10 N-terminal aa fragment of Sln2 286 (Sln2-4) did not display anti-Listeria activity. However, although the specific activity 287 of the trypsin resistant Sln2-5 variant (Table 2 ) was reduced five-fold relative to Sln2 288 (again when combined with Sln1; Table 1), it retained a similar spectrum of activity, 289 inhibiting species of Lactobacillus, Enterococcus and Listeria (as determined by well 290 diffusion assay; Fig. 5 ). It is thus apparent that the nine N-terminal residues of Sln2 291 are not essential for peptide function. 292 trypsin-resistant peptides, Sln1-5 and Sln2-3, revealed that their combined specific 296 activity (MIC 50 of 300 nM) was just 3.75-fold less than that of the wild type peptides 297 (80 nM) against L. monocytogenes NCTC 11994 (Fig. 6) . 298 299 Discussion 300
The naturally occurring two component bacteriocins, salivaricin P, abp118 and 301 salivaricin CRL1328 share greater than 95% homology (2, 12, 32) . While these 302 bacteriocins have shown promise in controlling intestinal pathogens in situ, a 303 fundamental understanding of how these peptides function is crucial, both in terms of 304 gaining regulatory approval for such applications and to assist in the design of 305 antimicrobial derivatives with improved functionality. Recent studies revealed the 306 pore forming ability of salivaricin CRL1328, and thus presumably of salivaricin P and 307 abp118, results in dissipation of both the transmembrane electrical potential and the 308 pH gradient of sensitive cells (32). While the synthetic salivaricin P components 309 display weak individual activity, this study confirmed that optimal synergistic 310 antimicrobial activity is achieved when the component peptides are combined at 311 nanomolar concentrations in a ratio of 1:1. We also demonstrated that the individual 312 peptides function in a sequential manner and it is established that Sln2, but not Sln1, 313 is capable of binding to the target cell membrane in the absence of its companion 314 peptide. While it is likely that this involves an interaction with a docking molecule or 315 receptor, studies of Sln2 peptides with altered chirality will be required to verify the 316 existence of a cellular receptor for Sln2. The subsequent addition of Sln1, to 317 potentially form a bacteriocin-membrane receptor complex, is then required for 318 optimal activity. 319
A variety of alterations of each of the component peptides were designed, 320 created and assessed with a view to enhancing the trypsin-resistance of salivaricin P 321 without dramatically reducing the antimicrobial activity of the bacteriocin. It was 322 noted that, in general, insertion of proline residues represented a very well tolerated 323 means of generating trypsin-resistant salivaricin variants. The least deleterious Sln1 324 variant was that in which both trypsin-sensitive residues were present (Sln1-5), with 325 adjacent proline residues introduced to confer trypsin resistance. While a comparable 326
Sln2 variant was not generated, it was noted that an additional proline insertion in 327 Sln2-2 did not further reduce its activity relative to Sln2-1, which like Sln2-2 also 328 contained an Arg10His substitution. In contrast, the most deleterious mutation of Sln1 329 involved a single histidine substitution of both trypsin-sensitive residues (Sln1-2). 330
Conversely, the conservative histidine substitution of both trypsin-sensitive residues 331 of Sln2 was well tolerated, with the corresponding variant, Sln2-3, being the most 332 active of all of the Sln2 variants. Assays with purified Sln1 peptides revealed a 333 consistent tendency for the peptides to become oxidised. It was established that this 334 oxidation occurred at Met37 and was absent in a Met37Leu variant of Sln1. The 335 reduced activity of the corresponding Sln1-6 peptide revealed that the methionine is 336 required for optimal activity, perhaps being required to facilitate correct peptide 337 folding or for the interaction of Sln1 with Sln2 or the target cell membrane. 338
Analysis of the trypsin-resistant N-terminally truncated derivative of Sln2, 339 Sln2-5, revealed that while these changes were deleterious, the truncated variant 340 continued to exhibit anti-listerial activity at nanomolar concentrations and possessed a 341 similar spectrum of inhibition to Sln2, when combined with Sln1. This finding is 342 significant given that, on the basis of the sequential action studies, it is necessary for 343 Sln2 to first bind to target cells and it is thus likely to be responsible for determining 344 target cell specificity. Interestingly, the natural salivaricin P variant, abp118, differs 345 from Sln2 with respect to two C-terminal amino acid changes (Ala43Thr and 346 His46Arg). The fact that the spectrum of inhibition of salivaricin P and abp118 also 347 differ (2), suggests the potential involvement of the C-terminal region of this peptide 348 in determining target cell specificity. Further alterations of the C-terminal residues of 349 Sln2 will be investigated to address this. Significantly, however, the variants 350 generated here demonstrate that a variety of mutations can result in the creation of 351 trypsin-resistant variants of the salivaricin P peptides without significantly altering the 352 length, net charge and, most importantly, potency of the bacteriocin. of bacteriocins (as with the abp118 and salivaricin P producers Lb. salivarius 361 UCC118 and Lb. salivarius DPC6005, respectively (5, 33)), the inherent protease 362 sensitivity of these peptides remains an issue. In this study we demonstrate the 363 potential to enhance the protective function of such salivaricin P-like bacteriocins. 364
While we acknowledge that the trypsin-resistant variants described in this study will 365 remain sensitive to other proteases encountered in the GIT, they represent an 366 important step forward in that it is now apparent that such beneficial traits can be 367 incorporated in a deliberate manner. These developments can in turn be incorporated 368 into the producing strain by site-directed mutagenesis for assessment of their efficacy 369 
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Sln2
KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 555
Abp118β
KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFTSCR 556
Sal β KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFTSCR 557 ****************************************** ** 558 
